Clinical Trial

SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC

Name: SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC — clinical trial record (NCT07489703)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase II, open-label, single-arm study evaluating the efficacy and safety of SHR-A1811 (a HER2-targeted ADC) combined with AK112 (a PD-1/VEGF bispecific antibody) in patients with HER2-amplified or overexpressed locally advanced or metastatic NSCLC.

Trial Details

NCT Number	NCT07489703
Lead Sponsor	Sun Yat-sen University
Conditions	Non-Small Cell Lung Cancer
Enrollment	30 participants
Start Date	2026-04-30
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-24